Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174940 · ClinicalTrials.gov registry record · Early Phase 1
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
A Early Phase 1 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
NCT01174940 is a Early Phase 1 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 22 participants.
The verdict
NCT01174940, a Early Phase 1 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
To study the effect of ECP with Uvadex® in conjunction with a standard myeloablative conditioning regimen on the incidence of acute and chronic GvHD in patients undergoing an allogeneic related or unrelated BMT or PBSC transplant, for treatment of hematologic or lymphoproliferative malignancies.
Interventions
- DRUG extracorporeal photopheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-06 |
| Est. Completion | 2015-08 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174940
The ClinicalTrials.gov registry entry for NCT01174940 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which extracorporeal photopheresis is the first listed.
NCT01174940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174940 about?
NCT01174940 is a clinical study titled "Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease". To study the effect of ECP with Uvadex® in conjunction with a standard myeloablative conditioning regimen on the incidence of acute and chronic GvHD in patients undergoing an allogeneic related or unrelated BMT or PBSC transplant, for treatment of hematologic or lymphoproliferative malignancies.
What is the current status of trial NCT01174940?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2010-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01174940?
The interventions under investigation include: extracorporeal photopheresis (DRUG).
Who is sponsoring clinical trial NCT01174940?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.